Cogent Biosciences
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2014-01-01
- Employees
- 164
- Market Cap
- $1B
- Website
- http://www.cogentbio.com
- Introduction
Cogent Biosciences, Inc. is a biotechnology company, which engages in the development of precision therapies for genetically defined diseases. It focuses on CGT9486, a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. The company was founded by Charles Wilson and Dario C...
Cogent Biosciences Announces Positive Updated Data from Ongoing Phase 2 APEX Trial
The article discusses the importance of enabling JavaScript for optimal app performance.
CSF1R Inhibition in Patients with Advanced Solid Tumors or Tenosynovial Giant Cell Tumor
Various researchers report financial relationships with pharmaceutical companies, including Deciphera, during and outside the conduct of the study.
© Copyright 2024. All Rights Reserved by MedPath